Navigation Links
Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2010

PALO ALTO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings from continuing operations of $0.87 per diluted share in the fourth quarter of fiscal year 2010, up 12 percent from $0.78 in the year-ago quarter.  Net earnings per diluted share from continuing operations for fiscal year 2010 climbed to $2.96, also up 12 percent from $2.65 in fiscal year 2009.  Including discontinued operations, net earnings were $0.87 per diluted share for the fourth quarter and $2.91 for the fiscal year.  Compared to the same periods in fiscal year 2009, fourth-quarter revenues grew 2 percent to $652 million and revenues for fiscal year 2010 rose by 6 percent to $2.4 billion.

Net orders rose by 12 percent to $777 million for the fourth quarter and increased by 10 percent to $2.6 billion for the fiscal year, excluding from the year-ago periods a $62 million proton therapy system order that has been cancelled.  Excluding the proton order, the year-ending backlog rose 10 percent to $2.2 billion.  Including the proton order in the year-ago periods, net orders rose 3 percent for the fourth quarter and 5 percent for the fiscal year, and the year-ending backlog rose 7 percent.

"Our Oncology Systems and X-Ray Products businesses each generated solid order gains and achieved double-digit increases in backlog with the help of strong demand for new products, particularly our TrueBeam™ system and flat panel detectors," said Tim Guertin, president and CEO of Varian Medical Systems.  "Total revenues expanded modestly, reflecting the economic challenges and slower order activity that we experienced in the previous year, particularly in North America.  Product and territorial mix shifts within the Oncology business, a comparatively stronger dollar, and product launch costs contributed to a decline in the company's margins for the fourth quarter, but margins were up for the year."

The company ended the fiscal year with $520 million in cash and cash equivalents and $43 million of debt. During the fourth quarter, the company spent $255 million to repurchase 4.8 million shares of common stock, including an accelerated buyback of 3.9 million shares.  The company ended the quarter with accounts receivable days sales outstanding of 82, an increase of one day from the year-ago quarter.

Oncology SystemsOncology Systems' fourth quarter revenues totaled $512 million, down 3 percent from the same period of fiscal year 2009.  Oncology revenues for fiscal year 2010 were $1.9 billion, up 4 percent from fiscal year 2009.  Fourth-quarter net orders were $657 million, up 15 percent, with a 24 percent gain in North America and a 7 percent increase in international markets.  Net orders for the fiscal year rose to $2.1 billion, up 10 percent from the last fiscal year, with a 4 percent gain in North America and a 16 percent increase in international markets.  

"Customers placed more than 60 orders for our TrueBeam radiotherapy and radiosurgery system during the quarter, bringing cumulative orders for this exciting new product to more than 125 units since its introduction in the second quarter of this year," said Guertin.  "TrueBeam together with RapidArc helped to stimulate a recovery in the North American oncology market.  Service added to growth for Oncology Systems and it now represents nearly 30 percent of annual orders and revenue for this business."

X-Ray ProductsFourth quarter revenues for the X-Ray Products business were $107 million, up 16 percent from the year-ago quarter, and revenues for fiscal year 2010 were $403 million, up 22 percent from the prior year.  Compared to the corresponding periods in fiscal year 2009, X-Ray Products' fourth quarter net orders rose 15 percent to $112 million, and fiscal year net orders rose 24 percent to $419 million.

"This was a record quarter for our X-Ray Products business with strong growth in orders and sales," Guertin said. "Flat panel detectors, including our newer panels for digital radiography, led the expansion in this business.   Orders for X-ray tubes grew solidly for the quarter and the year. Record sales volumes and a mix shift toward panel shipments contributed to strong gross margins and record quarterly operating earnings for this business."

OtherThe company's Other category, which is comprised of the Security and Inspection Products business, the Varian Particle Therapy business, and the Ginzton Technology Center, recorded fourth quarter revenues of $33 million, up 47 percent or $11 million from the year-ago period.  Revenues for fiscal year 2010 totaled $91 million, up 8 percent from fiscal year 2009.

Excluding the cancelled proton order, fourth quarter net orders in the Other category were $8 million, down $19 million from the year-ago quarter, and net orders for fiscal year 2010 totaled $61 million, down $27 million from the prior year.  "Tender award protests in the U.S. continued to hinder our security business," Guertin said.  "Consequently, the company restructured this business and booked a $2 million restructuring charge in the fourth quarter to bring costs in line with actual business activity."

Outlook "Strengthened order activity for our Oncology Systems business in the second half of this fiscal year as well as ongoing momentum in our X-Ray Products business has set the stage for better growth in the company's revenues and earnings in fiscal 2011," said Guertin.  "For fiscal year 2011, we believe that revenues and operating earnings could increase by 10 to 11 percent over fiscal 2010 totals and that net earnings per diluted share from continuing operations could rise around 14 percent to a range of $3.34 to $3.39.  For the first quarter of fiscal year 2011, total company revenues could increase by about 8 percent over the prior year, and net earnings per diluted share from continuing operations could also rise around 15 percent to a range of  $0.71 to $0.74."

Investor Conference CallVarian Medical Systems is scheduled to conduct its fourth quarter fiscal year 2010 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at where it will be archived for a year.  To access the call via telephone, dial 1-866-831-6270 from inside the U.S. or 1- 617-213-8858 from outside the U.S. and enter confirmation code 77390623.  The replay can be accessed by dialing 1-888-286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 92095527.  The telephone replay will be available through 5 p.m. PT, October 29, 2010.

For automatic "e-mail alerts" regarding Varian news, events, and new investor materials on the website, investors can subscribe on the company website:  For additional information, contact investor relations at 1 650 424-5834.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,300 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit

Forward-Looking Statements Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as TrueBeam and our radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms "expect," "can," "could," "believe," "estimate," "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, including the strength of any recovery from the global recession; the impact of recently enacted federal health care legislation and any further health care reforms, and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges in reducing or eliminating ongoing commitments retained from our discontinued research instruments business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.Varian Medical Systems, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(Unaudited)(Dollars and shares in millions, except per share amounts)Q4 QTR2010Q4 QTR2009Q4 YTD2010Q4 YTD2009Net orders


776.7755.32,494.82,380.6  Oncology Systems657.1569.62,076.41,890.7  X-Ray Products112.097.0418.9339.1  Other7.688.7(0.5)150.8Order backlog (1)




652.1642.02,356.62,214.1  Oncology Systems511.6526.81,862.11,797.8  X-Ray Products107.392.6403.2331.7  Other33.222.691.384.6Cost of revenues


375.9357.11,331.01,253.6Gross margin276.2284.91,025.6960.5  As a percent of revenues42.4%44.4%43.5%43.4%Operating expenses  Research and development  40.538.1156.7147.4  Selling, general and administrative  86.996.2334.7339.0Operating earnings 148.8150.6534.2474.1  As a percent of revenues22.8%23.5%22.7%21.4%Interest income/(expense), net0.2(0.2)(1.3)0.5Earnings from continuing operations before taxes149.0150.4532.9474.6Taxes on earnings 43.353.2165.4143.1Earnings from continuing operations  105.797.2367.5331.5  As a percent of revenues16.2%15.1%15.6%15.0%Loss  from discontinued operations – net of  taxes  (2)(0.7)(0.2)(7.1)(12.5)Net earnings


105.097.0360.4319.0Net earnings (loss) per share – basic:   Continuing operations


0.890.783.022.67   Discontinued operations  (2)(0.01)-(0.06)(0.10)   Net earnings per share


0.880.782.962.57Net earnings (loss)  per share – diluted:   Continuing operations$

0.870.782.962.65   Discontinued operations  (2)-(0.01)(0.05)(0.10)   Net earnings per share


0.870.772.912.55Shares used in the calculation of net earnings per share:    Average shares outstanding - basic119.0124.3121.8124.0Average shares outstanding - diluted121.4125.3124.0125.0(1)

Net orders for both Q4 QTR 2009 and Q4 YTD 2009 include $62 million for the Skandion Kliniken proton therapy system order that was cancelled in the first quarter of fiscal year 2010.(2 )

The operating results of ACCEL research instruments are classified as discontinued operations for all periods presented. Varian Medical Systems, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(In thousands)October 1, October 2, 2010 2009 (1)(Unaudited)AssetsCurrent assetsCash and cash equivalents$



553,529Accounts receivable, net591,677580,918Inventories363,933321,861Deferred tax assets and other205,513216,143Total current assets1,681,3441,672,451Property, plant and equipment562,763527,135Accumulated depreciation and amortization(294,836)(263,075)Property, plant and equipment, net267,927264,060Goodwill208,451210,346Other assets166,230161,391Total assets$



2,308,248Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$



116,093Accrued expenses287,851304,402Deferred revenues141,916130,588Advance payments from customers275,998226,964Product warranty53,23350,823Short-term borrowings20,0004,445Current maturities of long-term debt5,5259,005Total current liabilities903,541842,320Other long-term liabilities127,175130,751Long-term debt17,86923,394Total liabilities1,048,585996,465Stockholders' EquityCommon stock 118,007125,281Capital in excess of par value 508,366516,478Retained earnings and accumulated other comprehensive loss  648,994670,024Total stockholders' equity1,275,3671,311,783Total liabilities and stockholders' equity$




The condensed consolidated balance sheet as of October 2, 2009 was derived from audited financial statements as of that date.FOR INFORMATION CONTACT:Elisha Finney (650) 424-6803elisha.finney@varian.comSpencer Sias (650)

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015  Following an ... (NASDAQ: OGXI ) announced today that its Phase ... interim futility analysis of the intent-to-treat (ITT) population. In ... identified by the DMC. Both the DMC and OncoGenex ... expected in the second half of 2016, depending on ...
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Florida Hospital Tampa is the first health ... in the state of Florida. , vBloc® Therapy is a vagal blocking therapy, delivered via ... with a body mass index (BMI) of at least 40 to 45 kg, or a ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... , ... Califia Farms , one of the fastest growing natural beverage ... honors in Beverage World Magazine’s Global Packaging Design Awards, taking home the Gold in ... as a 2015 U.S.A. Taste Champion in the American Masters of Taste Championships for ...
(Date:12/1/2015)... Middletown, PA (PRWEB) , ... December 01, 2015 ... ... separate environments; however, there are professionals who believe that with innovative technologies and ... services allows the patient to get the benefit of a dual-approach to his ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- ... the company’s growing product line of food safety and seafood fraud prevention tools. ... nerka) – allow InstantLabs to offer fast, reliable species identification for the four ...
Breaking Medicine News(10 mins):